Somewhere in the neighborhood of 100 trillion bacteria live in the human gut, and they do not keep to themselves. As they grow and divide, many of them shed tiny membrane-bound particles, some no wider than a virus, loaded with fragments of bacterial cell walls, proteins, and genetic material. For decades, researchers assumed these particles stayed local, confined to the intestinal tract. A series of studies now published through early 2025 tells a different story: in aging bodies, these bacterial extracellular vesicles, or BEVs, slip through a weakening gut lining, enter the bloodstream, and set off immune alarms in organs that have never encountered a living microbe.
The implication is striking. The chronic, low-grade inflammation that physicians have long associated with aging, sometimes called “inflammaging” (a term coined by immunologist Claudio Franceschi in 2000), may not be an inevitable byproduct of cellular wear. It may be, at least in part, a response to microscopic debris leaking out of the gut.
The particles and how they escape
BEVs are spheres of bacterial membrane ranging from roughly 20 to 300 nanometers across. Their cargo is biologically potent: lipopolysaccharide (LPS), a component of bacterial cell walls known to activate the innate immune system; various proteins; and nucleic acids. A foundational review in Nature Reviews Immunology established that these cargos can trigger inflammatory signaling on contact with host immune cells, producing responses that protect against infection in the short term but damage tissue when they become chronic.
The challenge has been proving that vesicles actually reach the bloodstream in meaningful quantities. A key technical advance came with the development of standardized protocols, described in Nature Protocols, for separating BEVs from the confounding soup of lipoproteins, cell debris, and soluble proteins found in blood and stool. Without that separation, any signal from vesicles would be lost in background noise.
With those methods in place, researchers performed single-particle analysis on blood from both humans and mice and found that circulating BEV levels climb steadily with age. That increase tracked with measurable changes in intestinal barrier integrity, according to a 2023 study in Cell Reports. As the gut lining loosens, more vesicles escape. The pattern held across species, suggesting it reflects a conserved feature of mammalian biology rather than a quirk of one lab model.
Direct evidence of harm
Correlation is not causation, and the field has not stopped at observation. In a 2018 experiment reported in Experimental & Molecular Medicine, researchers purified nano-sized extracellular vesicles from mouse feces and injected them into healthy animals. The mice developed acute systemic inflammation, with immune activation persisting even in germ-free animals that harbored no live bacteria of their own. The vesicles alone, without any living microbe, were enough to provoke a body-wide inflammatory response.
Specific bacterial species appear to play distinct roles. Akkermansia muciniphila, a well-studied gut commensal, releases vesicles that regulate tight junction proteins in intestinal cells, directly influencing how permeable the gut wall becomes, as shown in research published in Experimental and Molecular Medicine. Loosening those junctions creates the very gateway through which other bacterial vesicles can enter the bloodstream, a feedback loop linking barrier breakdown to systemic inflammation.
Disease-specific work has sharpened the picture further. In a 2025 study published in Nature Communications, researchers examining ulcerative colitis patients found that bacterial vesicles coated with human IgA antibodies were concentrated in inflamed tissue. When those IgA-tagged vesicles were exposed to immune cells in the lab, they provoked far stronger inflammatory responses than uncoated vesicles did. The antibody coating appeared to mark the particles for heightened immune recognition, amplifying the damage.
And the phenomenon extends beyond bacteria. A separate 2025 paper, also in Nature Communications, profiled extracellular vesicles produced by gut archaea and confirmed they carry immunologically active payloads capable of triggering cytokine production. The finding means vesicle-driven immune signaling is not confined to one branch of microbial life. It may be a general feature of how the gut microbiome communicates with, and occasionally provokes, its host.
What researchers still cannot answer
The causal chain from “vesicles increase with age” to “vesicles drive age-related disease in humans” has not been closed. Most of the direct evidence comes from mouse models and cell culture. As of mid-2026, no published longitudinal human cohort study has tracked circulating BEV levels against clinical markers of inflammaging, such as interleukin-6 or C-reactive protein, over years or decades. The age-related rise in vesicles is well-documented, but whether it meaningfully accelerates conditions like cardiovascular disease, frailty, or neurodegeneration in people remains an inference, not a confirmed sequence.
Intervention trials are also missing. No controlled human study has tested whether reducing BEV translocation, through barrier-targeted therapies, microbiome modification, or vesicle-clearance strategies, lowers systemic inflammatory markers in older adults. The therapeutic promise is genuine but unproven in clinical settings.
Standardization remains a practical obstacle. The Nature Protocols workflow established a rigorous method for isolating BEVs, but cross-lab validation at scale has not been completed. Different isolation techniques can yield different vesicle populations, making it difficult to compare results across research groups. Until the field converges on shared standards for sample handling, particle counting, and cargo analysis, reported BEV counts may vary depending on who runs the assay.
Then there is the question of directionality. Aging brings changes in diet, medication use, and immune function, all of which reshape the microbiome and its vesicle output. How much of the observed rise in circulating BEVs reflects intrinsic barrier decline versus these external pressures is not yet clear. Disentangling cause from consequence will require carefully controlled human studies that measure vesicles alongside lifestyle variables, microbiome composition, and host genetics.
What about diet, probiotics, and “leaky gut” supplements?
Readers familiar with the wellness market will notice overlap between this research and popular claims about “leaky gut.” The science here is more precise: researchers are measuring specific particles crossing a specific barrier, not invoking a vague syndrome. But the practical question is fair. Can anything be done now to shore up the intestinal lining or reduce vesicle escape?
The honest answer is that no intervention has been tested in humans specifically for its effect on BEV translocation. Dietary fiber, which feeds short-chain fatty acid-producing bacteria known to support barrier integrity, has strong epidemiological backing for gut health broadly, but its effect on vesicle levels has not been measured in a clinical trial. Probiotic supplements, including those containing Akkermansia muciniphila, are commercially available, yet the relationship between Akkermansia vesicles and barrier function is complex: the same organism’s vesicles can both tighten and loosen junctions depending on context. No regulatory body has approved any product for reducing BEV-related inflammation.
For now, the most evidence-supported strategies for maintaining gut barrier function in aging are not exotic. They include adequate dietary fiber, regular physical activity, and cautious use of medications known to affect gut permeability, such as nonsteroidal anti-inflammatory drugs. These are not targeted BEV therapies. They are general measures supported by decades of gastroenterology research that happen to align with the emerging vesicle story.
Where this research is heading
The two 2025 Nature Communications papers on IgA-coated vesicles and archaeal vesicles represent the current frontier. They show that the field is moving beyond proof-of-concept toward understanding which vesicle populations matter most and how the host immune system sorts friendly signals from harmful ones. If standardized assays can be validated across laboratories, BEV levels in blood could eventually serve as a biomarker for gut barrier integrity and systemic inflammatory risk, a measurable readout that is more specific than broad markers like C-reactive protein.
The longer-term possibility, still speculative, is therapeutic: engineering vesicles that deliver anti-inflammatory cargo, developing drugs that reinforce tight junctions against vesicle escape, or designing microbiome interventions that shift the balance of vesicle-producing species. None of these approaches has reached human trials.
What the research has already accomplished is a shift in framing. Aging-related inflammation is no longer just a vague consequence of cells getting old. It has a geography (the gut barrier), a vehicle (bacterial vesicles), and a mechanism (immune activation by microbial cargo in the bloodstream). Whether that mechanism proves to be a major driver of human aging or a contributing thread among many, it has given scientists something they did not have before: a target they can see, count, and eventually try to control.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
